Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.virol.2005.06.016 http://scihub22266oqcxt.onion/10.1016/j.virol.2005.06.016 16043204!7111745!16043204     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 253.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 253.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Virology 2005 ; 340 (2): 174-82 Nephropedia Template TP {{tp|p=16043204|t=2005. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine |pdf=|usr=}}{{16043204}} gab.com Text Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine JO: Virology http://www.kidney.de/pget.php?&tw=1&pmid=16043204 #FOAvip Although the recent SARS coronavirus (SARS-CoV) that appeared in 2002 has now been contained, the possibility of re-emergence of SARS-CoV remains. Due to the threat of re-emergence, the overall fatality rate of approximately 10%, and the rapid dispersion of the virus via international travel, viable vaccine candidates providing protection from SARS are clearly needed. We developed an attenuated VSV recombinant (VSV-S) expressing the SARS coronavirus (SARS-CoV) spike (S) protein. In cells infected with this recombinant, S protein was synthesized, glycosylated at approximately 17 Asn residues, and transported via the Golgi to the cell surface. Mice vaccinated with VSV-S developed SARS-neutralizing antibody and were able to control a challenge with SARS-CoV performed at 1 month or 4 months after a single vaccination. We also demonstrated, by passive antibody transfer, that the antibody response induced by the vaccine was sufficient for controlling SARS-CoV infection. A VSV-vectored SARS vaccine could have significant advantages over other SARS vaccine candidates described to date. Twit Text FOAVip Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine ????Virology http://www.kidney.de/pget.php?&tw=1&pmid=16043204 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=16043204 #FOAvip English Wikipedia <ref>{{Cite pmid|16043204}}</ref> Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine #MMPMID16043204 Kapadia SU; Rose JK; Lamirande E; Vogel L; Subbarao K; Roberts A Virology 2005[Sep]; 340 (2): 174-82 PMID16043204show ga Although the recent SARS coronavirus (SARS-CoV) that appeared in 2002 has now been contained, the possibility of re-emergence of SARS-CoV remains. Due to the threat of re-emergence, the overall fatality rate of approximately 10%, and the rapid dispersion of the virus via international travel, viable vaccine candidates providing protection from SARS are clearly needed. We developed an attenuated VSV recombinant (VSV-S) expressing the SARS coronavirus (SARS-CoV) spike (S) protein. In cells infected with this recombinant, S protein was synthesized, glycosylated at approximately 17 Asn residues, and transported via the Golgi to the cell surface. Mice vaccinated with VSV-S developed SARS-neutralizing antibody and were able to control a challenge with SARS-CoV performed at 1 month or 4 months after a single vaccination. We also demonstrated, by passive antibody transfer, that the antibody response induced by the vaccine was sufficient for controlling SARS-CoV infection. A VSV-vectored SARS vaccine could have significant advantages over other SARS vaccine candidates described to date. |Animals[MESH] |Antibody Formation[MESH] |Cell Line[MESH] |Cricetinae[MESH] |DNA Primers[MESH] |Immunity, Cellular[MESH] |Kidney[MESH] |Mice[MESH] |Reverse Transcriptase Polymerase Chain Reaction[MESH] |Severe Acute Respiratory Syndrome/*immunology[MESH] |Severe acute respiratory syndrome-related coronavirus/genetics/*immunology[MESH] |Vaccines, Attenuated[MESH] |Vaccines, DNA[MESH] |Vesicular stomatitis Indiana virus/*immunology[MESH]Long-term protection from SARS coronavirus infection conferred by a si(epmc).pdf DeepDyve Pubget Overpricing